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Summary
The erythroleukemia developed by spi-1/PU.1 transgenicmice is amultistage process characterized by an early arrest of the
proerythroblast differentiation followed later on by malignant transformation. Herein, we report the presence of acquired
mutations in the SCF receptor gene (Kit) in 86% of tumors isolated during the late stage of the disease. Kit mutations affect
codon 814 or 818. Ectopic expression of Kit mutants in nonmalignant proerythroblasts confers erythropoietin independence
and tumorigenicity to cells. Using PP1, PP2, and imatinib mesylate, we show that Kit mutants are responsible for the auton-
omous expansion of malignant cells via Erk1/2 and PI3K/Akt activations. These findings represent a proof of principle for
oncogenic cooperativity between one proliferative and one differentiation blocking event for the development of an overt
leukemia.Introduction
Human tumors, as well as murine cancer models, progress by
the accumulation of genetic abnormalities in somatic cells, al-
lowing them to escape from control mechanisms involved in
cell differentiation, growth, and death. The acute Friend erythro-
leukemia that is induced in mice by the Friend virus spleen
focus-forming virus (SFFV) has provided an important model
to understand the multistage nature of leukemogenesis. The
Friend disease evolves in two stages. The first stage is charac-
terized by a growth factor-independent polyclonal proliferation
of erythroid progenitors, most of them undergoing terminal ery-
throid differentiation. The late stage ismarked by the emergence
of leukemic proerythroblastic clones, which are unable to differ-
entiate into mature red blood cells and are tumorigenic in vivo
(Ben-David and Bernstein, 1991). Three molecular events un-
derlying the progression of the Friend leukemia have been iden-
tified. During the early phase of the disease, the activation of
the erythropoietin (Epo) receptor (EpoR) by the gp55 glycopro-
tein encoded by the SFFV env gene makes the growth andCANCER CELL : DECEMBER 2005 $ VOL. 8 $ COPYRIGHT ª 2005 ELSEVIEdifferentiation of the proerythroblast Epo independent (Aizawa
et al., 1990; Li et al., 1990). In the late phase of the disease,
the transcriptional activation of the spi-1 gene by SFFV inser-
tional mutagenesis is correlated with the emergence of malig-
nant proerythroblastic clones (Moreau-Gachelin et al., 1988,
1989; Paul et al., 1989). In addition, mutations in the p53 gene
resulting in a loss of function are also detected in highly tumor-
igenic proerythroblasts isolated late in disease pathogenesis
(Ben-David et al., 1988; Munroe et al., 1990).
The product of the spi-1 gene is the transcription factor PU.1,
a member of the ETS protein family (Goebl et al., 1990; Klemsz
et al., 1990). PU.1 deletion causes failure in lymphoid and mye-
loid development, and extinction of PU.1 is required for normal
erythroid development (McKercher et al., 1996; Nutt et al.,
2005). Moreover, according to the cell lineage, the function of
PU.1 is dose dependent (DeKoter and Singh, 2000). These spa-
tial and temporal differences for Spi-1/PU.1 function may pro-
vide the basis for understanding the opposing roles of PU.1 in
leukemogenesis. Hypomorphic mutations of PU.1 have been
identified in rare human acute myeloid leukemia (AML), as wellS I G N I F I C A N C E
The ‘‘two-hit’’ model for leukemogenesis predicts that acute myeloid leukemia (AML) is the consequence of a collaboration between
two classes of mutations, one conferring a proliferative advantage and one blocking differentiation. The pathogenesis of acute eryth-
roleukemia in spi-1/PU.1 transgenic mice brings a direct validation to this concept. Spi-1/PU.1 overexpression in vivo induces a primary
impairment of erythroblast differentiation and creates conditions to select cooperating oncogenic events. The finding of activating mu-
tations in kit, which are detected in 86% of tumors, provides direct evidence for a second hit that induces proliferative signals that con-
tribute to malignancy. This model recapitulates many characteristics of AML in humans and provides tools to elucidate secondary ef-
fects of these mutations during disease initiation and progression.R INC. DOI 10.1016/j.ccr.2005.11.009 467
A R T I C L Eas in radiation-induced myeloid leukemia in mice (Cook et al.,
2004; Mueller et al., 2002; Suraweera et al., 2005). The targeted
knockdown of PU.1 demonstrates that a residual expression of
PU.1 in mice also induces AML (Rosenbauer et al., 2004). In the
murine Friend erythroleukemia, the upregulation of Spi-1/PU.1
is oncogenic (Moreau-Gachelin et al., 1988). The consequences
of a Spi-1 overexpression in proerythroblasts were deduced
from the pathological features occurring in spi-1 transgenic
(spi-1-TG) mice (Moreau-Gachelin et al., 1996). Spi-1-TG mice
develop a severe anemia and a large hepatosplenomegaly
(HS1 stage) due to the proliferation of proerythroblasts blocked
in their differentiation and dependent upon Epo for their survival
and growth. At the onset of the disease, erythroleukemic spi-1-
TG mice may be treated by repeated transfusions of red blood
cells. However, all animals relapse with hepatosplenomegaly
(HS2 stage) due to the proliferation of proerythroblasts that
are blocked in their differentiation but that have acquired the
ability to grow without Epo and to induce tumors in immunode-
ficient mice. The multistep erythroleukemic process in spi-1-TG
mice shows that a high level of Spi-1 in the proerythroblast con-
tributes to leukemic transformation by blocking the erythroid dif-
ferentiation (Moreau-Gachelin et al., 1996). These findings indi-
cate that additional genetic alterations are required to confer
proliferative and survival advantages to the erythroblast, but di-
rect evidence has been lacking. One approach to address the
question of events cooperating for leukemic transformation in
the spi-1-TG erythroblasts was to study the intracellular signal-
ing pathways in HS2 cells. We previously demonstrated that the
PI3-kinase/Akt and the PKC/Erk1/2 pathways were activated in
HS2 cells and that these two signaling pathways cooperated to
induce survival and proliferation of spi-1-TG proerythroblasts in
the absence of Epo (Barnache et al., 2001). These data raised
the question of the nature of the molecular events responsible
for such signaling dysregulations.
Cell growth and survival pathways are linked to multiple sig-
naling cascades through tyrosine phosphorylation processes.
Altered or elevated tyrosine kinase activities arising from muta-
tions or protein structure abnormalities have been implicated in
malignant hematopoiesis. A well-known example is the consti-
tutive tyrosine kinase activity of the Bcr-Abl oncoprotein ex-
pressed in human chronic myelogenous leukemia (Shtivelman
et al., 1985). Many mutations in receptor tyrosine kinases are
linked to both acute and chronic leukemia. For example,
somatic mutations in FLT-3 (FMS-like tyrosine kinase) are fre-
quently detected in AML (Abu-Duhier et al., 2000; Yamamoto
et al., 2001) and myelodysplasia (Horiike et al., 1997), whereas
somatic mutations in the Kit receptor for stem cell factor (SCF)
are mainly associated with mastocytosis (Pignon et al., 1997;
Tsujimura et al., 1996) and AML (Beghini et al., 2000; Gari
et al., 1999).
Here, we report the presence of acquired mutations in the Kit
gene in 86% of tumors isolated during the erythroleukemic pro-
gression in spi-1-TG mice. Mutations affected mainly codon
814, and occasionally codon 818, and conferred a ligand-
independent tyrosine kinase activity to Kit. We demonstrated
that ectopic expression of either one Kit mutant in HS1 cells
conferred Epo independence in vitro and tumorigenicity in vivo
to HS1 cells. Using PP1, PP2, and imatinib mesylate as phar-
macological inhibitors of Kit tyrosine kinase activity, we also
show that the growth factor-autonomous expansion of HS2
cells induced by Kit mutants occurred via the activation of the468PI3K/Akt and MAPK signaling pathways. Altogether, these find-
ings indicate an essential role for Kit mutations in the progres-
sion of erythroleukemia in spi-1-TG mice.
Results
Kit is constitutively activated in tumorigenic HS2 cells
from spi-1-TG mice
We previously reported that the MAPK and PI3K pathways were
constitutively activated in Epo-independent and tumorigenic
spi-1-TG proerythroblasts (HS2 cells) (Barnache et al., 2001).
To approach the causes leading to constitutive activations of
these signaling pathways, we performed a comparative analysis
of the pattern of proteins phosphorylated on tyrosine in three
HS1 cell lines and six HS2 cell lines derived from enlarged
spleen of mice during the early (HS1) and late (HS2) stages
of the leukemia. Western blotting of whole-cell extracts with
an antibody specific for phosphotyrosine residues (anti-P-Y anti-
body) showed that both the number and the level of tyrosine-
phosphorylated proteins in five HS2 cell lines were strongly
increased in comparison to HS1 cells (Figure 1A). One promi-
nent difference was the detection of 130–140 kDa tyrosine-
phosphorylated proteins, which were present in HS2 cells but
absent in HS1 cells. One possible candidate was the SCF recep-
tor Kit. Confirmation of this assumption was obtained by immu-
noprecipitation of cell lysates with an anti-Kit antibody followed
by an anti-phosphotyrosine immunoblotting. Kit was detected
as two isoforms (125 and 145 kDa) in both HS1 and HS2
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Figure 1. Expression and tyrosine phosphorylation of Kit in HS1 and HS2 cells
A: Whole-cell extracts prepared from the indicated HS1 and HS2 cells were
analyzed by Western blotting using anti-phosphotyrosine (P-Y) antibodies.
This blot was stripped, and an anti-actin antibody was used to visualize
the equal loading of proteins (bottom panel). Molecular weight standards
are indicated on the right.
B: Protein extracts from the indicated HS1 and HS2 cells were immunopreci-
pitated (IP) with anti-Kit antibody. The immunoprecipitates were analyzed
by Western blotting with anti-P-Y antibodies. This blot was then stripped,
and the anti-Kit antibody was used to verify Kit immunoprecipitation. Three
independent experiments gave the same results.CANCER CELL : DECEMBER 2005
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Figure 2. Genomic sequencing of the Kit gene at exon 17 and kinase activity of Kit mutants
A: Point mutations affect codons 814 and 818 of Kit. The nucleotide sequence of the relevant portion of Kit exon 17 from 663 HS1 spleen, 606 and 921 HS2 spleen
tumor, and 931 HS2 spleen tumor is shown. In 663 HS1 cells, the gene is wild-type, and the nucleotide affected by mutation in 606, 921, or 931 HS2 tumor is
underscored. In the 606 HS2 tumor, the mutation G/T at codon 814 changes Asp to Tyr. In the 931 HS2 tumor, G/T at codon 818 changes Asp to Tyr. As
the wild-type sequence is also detected in both cases, the mutation is a heterozygous mutation.
B: Constitutive activation of Kit in HS2 cells. Kit was immunoprecipitated from indicated HS1 and HS2 cell lysates using the anti-Kit antibody. The Kit immuno-
precipitates were incubated with [g-32P ATP], and the incorporated 32P was visualized by autoradiography (upper panel) before immunoblotting with anti-Kit
antibody (lower panel). Autoradiograms are representative of three experiments.immunoprecipitates (Figure 1B). However, in contrast to HS1
cells, where Kit was not tyrosine phosphorylated, the receptor
was phosphorylated on tyrosine in most HS2 cell lines. Thus,
HS1 andHS2 cell lines express Kit, but tyrosine phosphorylation
of the receptor is seen only in HS2 cells, suggesting that Kit
could be activated in these cells.
Kit is mutated in tumorigenic HS2 cells
Two mechanisms of Kit activation in malignant cells are known:
autocrine/paracrine stimulation of the receptor by its ligand
SCF, or acquisition of activating mutations. HS2 cells did not
produce detectable levels of SCF (our unpublished data), sug-
gesting that autocrine or paracrine mechanisms were unlikely.
Several mutations in either the juxtamembrane domain or
the catalytic domain have been described that lead to ligand-
independent activation of the Kit tyrosine kinase activity (Furitsu
et al., 1993; Tsujimura et al., 1996). Thus, we sequenced the full-
length kit transcripts in three HS2 cell lines (606, 921, and 931).
In two of them (606 and 921), a single nucleotidic change G/T
at position 2440 from the first nucleotide in the coding region
was detected (Figure 2A) leading to the substitution of aspartic
acid 814 for tyrosine (D814Y). In cell line 931, the D814Y muta-
tion was not found, but we identified a G/T substitution at po-
sition 2452 in exon 17 changing aspartic acid 818 to tyrosine
(D818Y). In the three cell lines, a wild-type kit cDNAwas also se-
quenced, revealing that normal and mutated alleles were tran-
scribed.
The 606, 921, and 931 cell lines were derived from the en-
larged spleens of spi-1-TG mice during the HS2 phase of the
disease. To assesswhether the Kit mutationswere already pres-
ent in vivo, Kit exon 17 encoding the D814 and D818 cDNACANCER CELL : DECEMBER 2005region was sequenced from DNA extracted from the primary
splenic tumors. The mutation G/T at position 2440 was identi-
fied on one allele, demonstrating that themutation had occurred
in vivo during the development of erythroleukemia. To search
further for the occurrence of thesemutations during progression
of erythroleukemia in spi-1-TG mice, we sequenced Kit exon 17
from DNAs prepared from 25 additional HS2 splenic tumors.
Data summarized in Table 1 show that the D814Y mutation
was present in 18 out of 28 samples, while occurrence of the
D818Y mutation was seen in two tumors. Rarely, mutations
changed aspartic acid 814 to valine (D814V) or histidine
(D814H) and aspartic acid 818 to valine (D818V). No mutation
in Kit exon 17 was detected in the 622 HS2 cell line. This was
in agreement with the fact that Kit was not tyrosine phosphory-
lated in extracts prepared from this cell line (Figure 1). It should
be noted that 622 cells were previously characterized for Epo
autocriny, which accounted for growth autonomy (Moreau-
Gachelin et al., 1996). All of these leukemia retained the normal
Table 1. Kit mutations in HS2 tumors
Codon 814 818
Nucleotide wt GAC GAT
mut TAC GTC CAC TAT GTT
Amino acid wt D D
mut Y V H Y V
HS2 sample number 28 18 2 1 2 1
Mutations (mut) were identified in 24 spleen tumors among 28 tested. Point
mutations affect codons 814 and 818, which are both in exon 17. The wild-
type (wt) allele was sequenced in each tumor.469
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Figure 3. Enforced expression of KitD814Y and KitD818Y in HS1 cells confers Epo independence and tumorigenicity
A: Expression of Kit mutants in whole lysates from 663 HS1 cells transfected with either pEF-BOS and pMSCV-NeoR (M1), or pEF-BOS-KitD814Y and pMSCV-NeoR
(4A and 4B), or pEF-BOS-KitD818Y and pMSCV-NeoR (8A and 8B), or pEF-BOS-KitWT and pMSCV-NeoR (KW) cultured in the presence of Epo or SCF. Lysates were
analyzed by Western blotting using anti-P-Y antibodies. The same membrane was reprobed with anti-Kit antibodies.
B: 663 HS1 cells transfected with expression vectors for KitD814Y (663-4A cells) or KitD818Y (663-8A cells) or empty vector (663-M1 cells) were cultured for the
indicated times in the presence or absence of Epo.
C: 663 HS1 cells transfected with expression vectors for Kitwt (663-wt cells) were cultured for the indicated times in the presence or absence of Epo or SCF. The
mean number of living cells and standard deviations were determined from three experiments.Kit allele. Finally, the Kit exon 17 nucleotide sequence was de-
termined from six HS1 spleens, and no mutation was detected.
To confirm that G/T substitution at residues 814 and 818 of
Kit were activating mutations, kinase activity of Kit was directly
measured in immunoprecipitates from 606 and 931 HS2 cells
using an in vitro assay with radiolabeled ATP. Autoradiograms
(Figure 2B) show that Kit was phosphorylated in extracts from
both mutated cell lines, whereas phosphorylated forms of Kit
were not detected in extracts from 663 HS1 cells. Altogether,
these data show that both Kit mutations in HS2 cells lead to a li-
gand-independent kinase activity of this receptor and suggest
that themutation of Kit is a recurrent genetic alteration occurring
during the leukemic progression in spi-1-TG mice.
Expression of KitD814Y and KitD818Y mutants confers
Epo independence and promotes tumorigenicity
to HS1 spi-1-TG proerythroblasts
The identification of Kit mutations in 86% of HS2 tumors sug-
gested that they could be a causal factor in the growth factor in-
dependence and/or tumorigenicity of HS2 proerythroblasts. To
determine the phenotypic consequences related to the expres-
sion of KitD814Y or KitD818Y in leukemic cells, the expression of Kit
mutants was enforced in Epo-dependent 663 and 633HS1 cells.470Results with both cell lines were similar, and only data with 663
cells are detailed.
Stable populations of 663 HS1 cells were generated with ex-
pression constructs for KitD814Y (663-4 cells) or KitD818Y (663-8
cells). Pools of G418-resistant cells were used to avoid effects
of clonal selection and amplified in the presence of Epo. For
each mutation, two independent pools (A and B) were retained
for further study. 663 HS1 cells were also transfected with an ex-
pression construct forwild-typeKit (663-KWcells) or a neomycin
resistance gene vector (663-M1) to serve as controls. Whole ex-
tracts from transfected cells were analyzed by Western blotting
using the anti-phosphotyrosine antibody. Then, the blots were
reprobed with the anti-Kit antibody. Tyrosine-phosphorylated
proteins corresponding to Kit were detected in cells transfected
withKitD814Y- orKitD818Y-expressing vectors (Figure 3A)butwere
absent in both control cells cultured in thepresenceof Epo. In the
663-KW cells, the phosphorylated forms of Kit were only de-
tected when cells were cultured in the presence of SCF (Fig-
ure 3A).
We first examined whether the growth of the 663-4A and 663-
8A cells was changed with regard to their Epo dependency. Epo
starvation did not modify significantly the growth characteristics
of these cells (Figure 3B). Similar results were obtained forCANCER CELL : DECEMBER 2005
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Figure 4. Effects of PP1 and imatinib mesylate on
the proliferation of 606 HS2 cells and the kinase
activity of KitD814Y
A: Proliferation of 606 HS2 cells harboring the Kit
D814Y mutation and 663 HS1 cells transfected
with expression vectors for KitD814Y (663-4A cells)
in the presence of PP1 (4 mM) and in the pres-
ence (1 U/ml) or in the absence of Epo.
B: Proliferation of 606 HS2 cells and 663-4A cells in
the presence of imatinib mesylate (IM; 0.75 mM)
and in the absence of Epo. Viable cells were
counted at indicated times. The mean number
of living cells and standard deviations were de-
termined from three experiments.
C: In vitro sensitivities of the kinase activity of
KitD814Y to PP1, PP2, and IM. Kit was immunopreci-
pitated from 606 HS2 cell lysates using the anti-
Kit antibody. The Kit immunoprecipitates were
treated or not with the various inhibitors at the in-
dicated concentrations and subsequently sub-
jected to an autophosphorylation reaction in
the presence of [g-32P ATP]. Kit autophosphoryla-
tion was visualized by autoradiography (upper
panel). Receptor loading was controlled by
immunoblotting with anti-Kit antibodies (lower
panel). Autoradiograms are representative of
three experiments.663-4B and 663-8B cells (data not shown). In contrast, control
NeoR-transfected 663-M1 cells remained unable to proliferate
in the absence of Epo. With regard to 663-wt cells overexpress-
ing Kitwt, their growth was strictly dependent on either Epo or
SCF (Figure 3C). These results demonstrate that the enforced
expression of a mutated form of Kit (KitD814Y or KitD818Y) abol-
ishes the Epo requirement of HS1 cells for growth and survival.
Next, the oncogenic potential of 663-4 or 663-8 cells (pools A
and B) expressing KitD814Y or KitD818Y was assessed by subcu-
taneous injection of cells into immunodeficient mice, since re-
cipients having a genetic background compatible with that of
spi-1-TG mice were lacking. Within 2 weeks, all nude recipients
(seven per cell line) developed solid tumors (0.5–1.5 cm diame-
ter) at the injection site. Tumor efficiencies (100%) and size were
similar to those observed after engraftment of HS2 cells (606
and 931). NeoR-expressing cells (663-M1 cells) as well as 663
HS1 cells failed to develop tumors. Kit exon 17 from DNAs ex-
tracted from subcutaneous tumors was sequenced. The ex-
pected mutations were detected, demonstrating that tumors
derived from the injected cells (data not shown). Thus, ectopic
expression of KitD814Y or KitD818Y confers tumorigenicity to
HS1 cells.CANCER CELL : DECEMBER 2005Proliferation of HS2Kit D814Y cells is inhibited by PP1
and PP2 but not by imatinib mesylate
To address more directly the role of Kit mutations found in HS2
cells, we used three different pharmacological inhibitors of Kit
kinase activity. PP1 and PP2 are compounds that inhibit several
tyrosine kinases, including both the wild-type and mutated
forms of Kit (Tatton et al., 2003; Zermati et al., 2003). 606 HS2
cells harboring the KitD814Y mutation and 663-4A cells express-
ing an ectopic KitD814Y were grown in the presence of either PP1
or PP2. Addition of PP1 (4 mM) to the culture medium completely
inhibited cell growth, but the inhibition was not observed in the
presence of Epo, ruling out a nonspecific cytotoxic effect of
PP1 on the cells (Figure 4A). Similar data were obtained with
PP2 used at an identical concentration and with 663-4B
KitD814Y-transfected cells (data not shown). Imatinib mesylate
(also called STI571 or Gleevec) is a compound shown to inhibit
the kinase activity of a wild-type Kit (Heinrich et al., 2000), but
not a Kit mutated on residue 816 in human (Ma et al., 2002; Zer-
mati et al., 2003). Human codon 816 is the equivalent of codon
814 in the mouse. In contrast to data obtained with PP1 and
PP2, the proliferation of 606 or 663-4 cells was not significantly
affected by the addition of imatinib mesylate (0.75 mM)471
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Figure 5. Effects of PP1 and imatinib mesylate on
the proliferation of 931 HS2 cells and the kinase
activity of KitD818Y
A: Proliferation of 931 HS2 cells harboring the Kit
D818Y mutation and 663 HS1 cells transfected
with expression vectors for KitD818Y (663-8A cells)
in the presence of PP1 (4 mM) or imatinib mesy-
late (IM; 0.75 mM) and in the presence (1 U/ml)
or in the absence of Epo. Viable cells were
counted at indicated times. The mean number
of living cells and standard deviations were de-
termined from three experiments.
B: In vitro sensitivities of KitD818Y to PP1, PP2, and
IM. Kit was immunoprecipitated from 931 HS2
cell lysates with anti-Kit antibodies. Kit immuno-
precipitates were treated or not with the various
inhibitors at the indicated concentrations and
subsequently subjected to an autophosphoryla-
tion reaction in the presence of [g-32P ATP]. Kit
autophosphorylation was visualized by autoradi-
ography (upper panel). Receptor loading was
controlled by immunoblotting with anti-Kit anti-
bodies (lower panel). Autoradiograms are repre-
sentative of three experiments.(Figure 4B). Similar results were obtained when the expression
of KitD814V was enforced in 663 or 633 HS1 cells.
Next, the effects of PP1, PP2, or imatinib mesylate on Kit ki-
nase activity were evaluated in autophosphorylation kinase as-
says performed with Kit immunoprecipitates prepared from
606HS2 cell extracts. Reprobingwith the anti-Kit antibody dem-
onstrated equivalent amounts of Kit in each immunoprecipitate.
Addition of increasing concentrations of PP1 and PP2 to the
kinase assay impeded the autophosphorylation of KitD814Y in
a dose-dependent manner, while no effect was seen when ima-
tinib mesylate was added at increasing concentrations up to
2 mM (Figure 4C). Thus, 606 HS2 cells carrying the KitD814Y mu-
tation and 663-4A cells expressing an ectopic KitD814Y are
equally responsive to the growth inhibitory effects of PP1 and
PP2, and the inhibition of cell proliferation is correlated to the
biochemical effects of PP1 and PP2 on the constitutive Kit ki-
nase activity. In contrast, these cells are not affected by imatinib
mesylate, which is unable to inhibit KitD814Y tyrosine kinase ac-
tivity in vitro.
Proliferation of HS2Kit D818Y cells is inhibited
by PP1, PP2, and imatinib mesylate
Similarly, we examined the effects of PP1, PP2, and imatinib
mesylate on the growth of 931 HS2 cells that harbor the472D818Y mutation in Kit and on the growth of 663-8A cells ex-
pressing an ectopic KitD818Y. In contrast to cells with the
D814Y mutation, imatinib mesylate (0.75 mM) inhibited the au-
tonomous growth of each cell type as did PP1 (4 mM) and PP2
(data not shown) (Figure 5A). Comparable results were obtained
with 663-8B cells (data not shown). Inhibition of cell proliferation
was abrogated when Epo was present in the culture medium,
confirming that PP1, PP2, and imatinib mesylate targeted spe-
cifically the Epo-independent proliferation of HS2 cells. In addi-
tion, these drugs exerted a dose-dependent inhibitory effect on
the constitutive kinase activity of KitD818Y when added to the
in vitro kinase assay performed with Kit immunoprecipitates
from 931 HS2 cells (Figure 5B). Thus, PP1, PP2, and imatinib
mesylate inhibit the constitutive kinase activity of KitD818Y as
well as arresting the autonomous proliferation of both 931 HS2
cells and 663-8A cells.
The MAPK and PI3K/Akt pathways are activated
downstream from KitD814Y and KitD818Y
MAPK and PI3K/Akt pathways are constitutively activated in
HS2 cells (Barnache et al., 2001). Thus, it could be hypothesized
that the expression of Kit mutants in HS2 cells may mediate
these constitutive signaling activations. We first investigated
whether the activations of MEK/Erk1/2 and PI3K/Akt pathwaysCANCER CELL : DECEMBER 2005
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cell extracts were subjected to immunoblotting with antibodies indicated on the left of the panels. Western blots are representative of three independent
experiments.were sensitive to PP1, PP2, and imatinib mesylate in 606 and
931HS2 cells.Wemeasured the total and phosphorylated levels
of Erk1/2 and Akt with appropriate antibodies in whole-cell ex-
tracts. Western blots in Figure 6A show that the constitutive
phosphorylations of Erk1/2 or Akt were totally abolished in cell
lines cultured in the presence of both PP1 (4 mM) or PP2
(4 mM) and the MEK inhibitor U0126 (20 mM) or the PI3K inhibitor
LY294002 (10 mM). Comparable results were obtained with 663
HS1-transfected cells expressing either KitD814Y (663-4A cells)
or KitD818Y (663-8A cells) in Figure 6B or KitD814V (data not
shown). These data indicate that the constitutive activation of
both Erk1/2 and PI3K/Akt pathways requires signaling inhibited
by PP1 and PP2.
Finally, the effects of imatinib mesylate (0.75 mM) on the con-
stitutive activation of MEK/Erk and PI3K/Akt pathways were
compared in KitD814Y- versus KitD818Y-expressing cells (Fig-
ure 6). Both Erk1/2 and Akt phosphorylations were abolished
by imatinib mesylate treatment in cells expressing the D818Y
mutation (931 HS2 and 663-8A cells). In contrast, no reduction
in phosphorylation of Erk1/2 or Akt was detected in cells ex-
pressing KitD814Y (606 HS2 and 663-4A) after treatment with
this compound. The same results were observed for KitD814V-
expressing cells (data not shown). Thus, the ability of imatinib
mesylate to inhibit the constitutive activation of the Erk1/2 and
Akt pathways depends on the mutation on Kit and is strictly cor-
related to the effects of this drug on cell growth. Altogether,
these data demonstrate that mutations on Kit in malignant
HS2 proerythroblasts are correlated to the activation of down-
stream Erk1/Erk2 and Akt signaling pathways.
SCF and Epo cooperate to sustain the proliferation
of HS1 cells
Our initial studies failed to detect a significant growth depen-
dence of spi-1-TG proerythroblasts on cytokines other than
Epo (Moreau-Gachelin et al., 1996). The demonstration that
SCF receptors were expressed in HS1 cells raised the question
of a potential role for this receptor in HS1 cells. Accordingly, we
reevaluated the sensitivity of HS1 cells to SCF. Figure 7A shows
that SCF alone (100 ng/ml) could sustain the growth of 663 HS1CANCER CELL : DECEMBER 2005cells, though with a poor efficiency (even at higher concentra-
tions), since cell numbers were 50% reduced at 48 hr when
compared to cells grownwith Epo (1 U/ml). This SCF-dependent
growth was related to an activation of Kit, since a tyrosine-
phosphorylated form of Kit was detected in immunoprecipitates
from 663 HS1 cells stimulated by SCF, whereas it was absent in
Epo-stimulated cells (Figure 7B). It was also related to the phos-
phorylation of Erk1/2 and Akt, although Erk1/2 activation was
lower in 663 HS1 cells cultured in the presence of SCF than in
those cultured in the presence of Epo (Figure 7C). With regard
to 663KW-cells that overexpress Kitwt, Epo or SCF induced
a similar cell proliferation (Figure 3C) as well as equivalent levels
of Erk1/2 and Akt activations (Figure 7D). Moreover, PP1
(4 mM) and imatinib mesylate (0.75 mM) abolished these SCF-
dependent processes (Figures 7D and 7E). This indicated that
SCF, like Epo, was able to trigger proliferative signals leading
to Erk1/2 and Akt activations in HS1 cells.
Finally, we investigated whether SCF could cooperate with
Epo to induce 663 HS1 cells to proliferate. Cells were cultured
in the presence of a combination of SCF (100 ng/ml) and/or
a suboptimal dose of Epo (0.05 U/ml). The growth of 663 HS1
cells was significantly reduced in the presence of a low Epo con-
centration (0.05 U/ml) or with SCF alone (100 ng/ml), as com-
pared the optimal growth obtained with Epo at 1 U/ml. However,
when SCF (100 ng/ml) was combined with Epo (0.05 U/ml), cell
growth was restored to optimal levels obtained with Epo at
1 U/ml (Figure 7F). Similar results were observed with two other
HS1 cell lines (data not shown). This demonstrates that SCF is
not an optimal growth factor by itself for spi-1-TG proerythro-
blasts but can cooperate with Epo to drive the proliferation of
HS1 cells, a finding that further supports a role for SCF in the
expansion of HS1 cells in vivo.
Discussion
The erythroleukemia in spi-1/PU.1 transgenic mice evolves as
amultistep process (Moreau-Gachelin et al., 1996).Within about
4months after birth, mice develop a severe anemiawithmassive
infiltration of the spleen by erythroid precursor cells blocked at473
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pendent upon Epo for their proliferation and are unable to pro-
duce tumors when transplanted into secondary hosts (HS1
stage). In a second stage, fully malignant proerythroblasts
emerge that are growth factors independent for proliferation
and tumorigenic in vivo (HS2 stage). This multistage pathology
indicates that overexpression of Spi-1 is directly involved in
the erythroid differentiation blockade but is not sufficient to pro-
mote full malignancy.
With the aim of identifying oncogenic events involved during
leukemia progression, we found monoallelic mutations in the
Kit gene in 86% of the tumors isolated during the HS2 stage
of the disease. These mutations were gain-of-function, confer-
ring a ligand-independent tyrosine kinase activity to Kit. The rel-
evance of Kitmutations in the erythroleukemic process was as-
sessed through the analysis of phenotypic changes generated in
HS1 cells by an ectopic expression of Kit mutants. These cells
acquired an autonomous proliferation in vitro and a tumorigenic
phenotype in vivo. Using pharmacological inhibitors of Kit, we
demonstrate that Kit mutations released the proerythroblast
from Epo dependency via the constitutive activation of the
PI3K/Akt and Erk1/2 signaling pathways. Thus, mutations in
Kit appear to be master oncogenic events in the progression
of the proerythroblast toward malignancy.474Kit is a class III tyrosine kinase receptor that belongs to the
same subfamily as the receptors for PDGF, CSF-1, and FLT3 li-
gands. It consists of an extracellular domain with five immuno-
globulin-like domains, a single transmembrane domain, and
an intracytoplasmic kinase domain divided into an ATP binding
region and a phosphotransferase region (Qiu et al., 1988;
Yarden et al., 1987). Kit activation is triggered by SCF binding,
which induces receptor dimerization followed by activation of
the intrinsic tyrosine kinase and receptor trans-phosphorylation
on specific tyrosine residues (Rottapel et al., 1991). Subse-
quently, signaling pathways including MAPK, PI3K, and Src ki-
nase pathways can be activated (Timokhina et al., 1998; Wand-
zioch et al., 2004). Different mutations, which induce the
constitutive activation of Kit and lead to proliferative disorders,
have been described in human. Such mutations are of two
types. The first type comprises point mutations resulting in
ligand-independent catalytic activity of Kit (Moriyama et al.,
1996). Selective residues are affected in the phosphotransfer-
ase domain, such as the especially frequent mutation on residue
816 that converts Asp to a variety of amino acids (Val, Tyr, or
His). Such mutations are found in patients with mastocytosis
(Longley et al., 1996; Pignon et al., 1997) and AML (Beghini
et al., 2000; Wang et al., 2005). Mutations of the second type
are either point mutations or variable deletions in theCANCER CELL : DECEMBER 2005
A R T I C L Ejuxtamembrane domain of the receptor and were found in hu-
man gastrointestinal stromal tumors (Chen et al., 2003; Hirota
et al., 1998). In mice, Kit mutations affecting D814 have been de-
scribed in one mastocytoma cell line (Tsujimura et al., 1994) and
in one stroma-independent variant of an erythroleukemic cell
line (Leslie et al., 1998).
The implication of Kit mutants in the malignant phenotype of
HS2 proerythroblasts was demonstrated through cellular effects
of various pharmacological inhibitors on the Kit kinase activity.
Imatinib mesylate inhibits both the wild-type Kit and the juxta-
membrane Kit mutants (Akin et al., 2004; Heinrich et al., 2000).
With regard to the Kit mutants in the phosphotransferase do-
main, their sensitivity to imatinib mesylate depends on the mu-
tation (Ma et al., 2002; Zermati et al., 2003). Indeed, this drug
neither altered the constitutive kinase activity of KitD814Y in vitro
nor affected the growth of HS2 cells with a KitD814Y mutation. In
contrast, imatinibmesylate inhibits the Epo-independent growth
of HS2 cells harboring the KitD818Ymutation aswell as the kinase
activity of KitD818Y in vitro, strongly arguing for a prime role of
KitD818Y in signaling for growth autonomy. Tatton et al. showed
that PP1 and PP2 had significant activity against both the wild-
type Kit and the D816 mutant (Tatton et al., 2003). Indeed, PP1
and PP2 abolished the tyrosine kinase activity of KitD814Y, and
we established that they also inhibit the tyrosine kinase activity
of KitD818Y in vitro. Consistent with these biochemical effects,
PP1 and PP2 inhibited drastically the autonomous growth of
HS2 cells or the growth of HS1 cells rendered growth factor in-
dependent by the exogenous expression of KitD814Y or KitD818Y.
These data support a mechanistic link between the expression
of activated Kit mutants and cellular responses to drugs. Kit mu-
tants mediate the activation of Erk1/2 and Akt in HS2 cells as
well as in HS1 cells ectopically expressing KitD814Y or KitD818Y.
Thus, the activations of Erk1/2 and Akt downstream from Kit
mutants are sufficient to explain the growth factor-autonomous
expansion of HS2 cells. The molecular links involved in these
signaling pathways are currently under investigation.
Kit is expressed in HS1 cells, raising the question of a role for
SCF in favoring expansion of the erythroblastic compartment in
the preleukemic phase. Epo and SCF are two critical regulators
for erythropoiesis. In fetal livers from mice deficient in Epo or
Epo-R, BFU-E and CFU-E do not mature into erythrocytes
(Wu et al., 1995b). Loss-of-function mutations at the w locus,
which encodes the Kit gene, or the sl locus, which encodes
the SCF gene, result in particular in a depletion in erythroid pre-
cursors at the BFU-E/CFU-E transition (Chabot et al., 1988;
Geissler et al., 1988). A cooperation of SCF and Epo in the mat-
uration and proliferation of erythroid progenitor cells around the
CFU-E stage is also well documented (Panzenbock et al., 1998;
von Lindern et al., 2001). It is proposed that Kit activates Epo-R
by a physical association leading to tyrosine phosphorylation,
a mechanism that provides a molecular explanation for the co-
operative effects of Epo and SCF on erythropoiesis (Wu et al.,
1995a). The acute expansion of the erythroid compartment in-
tending to compensate the deficit in differentiated red blood
cells in the diseased spi-1-TG mice takes place in the presence
of SCF in the bone marrow and splenic microenvironments. In
addition, our present data showing that SCF cooperates effi-
ciently with Epo to induce in vitro proliferation of HS1 cells
strengthen the hypothesis that both Epo and SCF may account
for the amplification of the HS1 cell compartment in vivo. In this
context, activatingmutations occurring on a gene involved in theCANCER CELL : DECEMBER 2005expansion of preleukemic HS1 cells appear to be selection
events capable of conferring a strong proliferative advantage
leading to the emergence of malignant clones.
Because the high frequency of Kit mutations suggests
a strong specificity with regard to the cooperation of Spi-1
and Kit for erythroleukemic progression, we investigated
whether a constitutive activated form of Flt3, as frequently de-
tected in human AML (Yamamoto et al., 2001), could also coop-
erate with Spi-1 during erythroleukemic progression. Indeed,
the ectopic expression of a mutated Flt3 (D835Y) in HS1 cells
renders these cells growth factor independent, suggesting
that a cooperation of Spi-1 with activated tyrosine kinases other
than Kit is possible (unpublished data). However, as expected
from their erythroblastic nature (Adolfsson et al., 2005), Flt3 is
not expressed in HS1 and HS2 cells. This reinforces our hypoth-
esis that selection for Kit mutations in leukemic HS2 cells was
related to the function of Kit in preleukemic HS1 cells.
Other oncogenic alterations were observed in HS2 tumors.
Among the four HS2 tumors that did not harbor Kit mutations,
two secreted Epo, indicating that Epo autocriny may be an al-
ternative cooperative pathway (Moreau-Gachelin et al., 1996).
Loss of function by mutations in the p53 gene have been iden-
tified in 60% of HS2 spleen tumors (Barnache et al., 1998). Kit
mutations were detected with the same frequency in tumors
with a p53 genotype that was either wild-type or mutated.
Thus, p53 deficiency cannot be considered as a cooperating
oncogenic event in this erythroleukemic process. Neverthe-
less, it cannot be excluded that other alterations than Kit mu-
tation participate in in vivo progression from the HS1 to the
HS2 stage.
Studies of oncogenic alterations in human AML led to the
proposal of a ‘‘two-hit’’ model of leukemogenesis (Gilliland,
2001). In this model, an acute leukemia would arise from the co-
operation between one class of mutations that interferes with
differentiation and a second class of mutations that confers a
proliferative advantage to cells. Indeed, in some human AML,
combinations of dual mutations in the transcription factor
AML1 and the kinase receptors FLT3 or Kit have been reported
(Beghini et al., 2000;Matsuno et al., 2003;Wang et al., 2005) and
are a poor prognostic factor (Care et al., 2003). Acute erythroleu-
kemias in spi-1-TG mice as well as in Friend virus-infected mice
add strong support to the concept that aberrations in transcrip-
tion factors and tyrosine kinases are required for overt leukemia.
In the Friendmodel, the SFFV-infected erythroleukemic cells are
blocked in their differentiation as a consequence of Spi-1 over-
expression. Their growth and survival no longer depend on Epo
because of the activation of Epo-R by the viral gp55 (Muszynski
et al., 1998; Nishigaki et al., 2000), alleviating the need for selec-
tion of an oncogenic signaling event. Indeed, no Kit mutation
was detected in Friend tumor cells (our unpublished data). In
the spi-1-TG mice, the overexpression of Spi-1 prevents ery-
throid differentiation, and the resulting anemia induces a com-
pensatory expansion of the proerythroblastic compartment.
Then, the spi-1-TG mice are predisposed to clonal disorders
that affect the erythroid lineage. In most of the cases, Kit muta-
tions appear as the second and crucial hit that is associatedwith
the progression of proerythroblasts toward malignancy. Thus,
this model of leukemic transformation requires the collaboration
of at least one proliferative and one differentiation blocking
event. It underscores the similarities betweenmouse and human
leukemias and appears as a fruitful experimental model to475
A R T I C L Edissect the respective roles of crucial genes affecting the leuke-
mic process.
Experimental procedures
Transgenic mice and cell lines
The spi-1-TGmice were generated by germinal insertion of a spi-1 transgene
whose transcription is driven by the SFFV LTR. HS1 cells and HS2 cell lines
were established frombonemarrow and enlarged spleen of leukemicmice as
described previously (Moreau-Gachelin et al., 1996). Experiments on mice
were performed in accordance with relevant institutional guidelines from
the Direction De´partementale des Services Ve´te´rinaires de Paris (approval
16-08-2004). Cells were cultured in a minimum essential medium (aMEM;
GibcoBRL) supplemented with 10% fetal calf serum (FCS; GibcoBRL) and
1 U/ml of recombinant human Epo (Cilag, Levallois-Perret, France) when in-
dicated.
For growth kinetics, cells were plated at 2 3 105 cells/ml. LY294002 (PI3
kinase inhibitor; Sigma), U0126 (MEK inhibitor; Promega), PP1 (Biomol),
PP2 (Calbiochem), and imatinib mesylate (Novartis Pharma, Basel, Switzer-
land) were added at the indicated concentrations in culture medium. Viable
cell numbers were monitored by 0.2% of Trypan blue exclusion staining
(Sigma-Aldrich).
Immunoprecipitation and Western blotting
Cells were lysed at 2 3 107 cells/ml in ice-cold lysis buffer (10 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 5 mM EDTA, 20 mM NaF, 25 mM b-glycerophos-
phate, 1 mM Na pyrophosphate, 10% glycerol, 1% NP40, 1 mM Na3VO4,
13 protease inhibitor; Roche). Lysates were centrifuged at 18,000 3 g for
15 min at 4ºC. Supernatants were incubated with Kit antibodies for 2 hr at
4ºC. The immunoprecipitates bound to protein G Sepharose (Amersham)
were washed extensively with 1% NP40 lysis buffer and 0.1% NP40 lysis
buffer. Whole-cell extracts or immunoprecipitates were fractionated by
SDS-PAGE, blotted, and visualized by the enhanced chemiluminescence
(ECL) detection system (Amersham) as previously described (Barnache
et al., 2001). Primary antibodies included 4G10 anti-phosphotyrosine anti-
body (UBI); rabbit immune serum anti-Kit, anti-phospho-Akt (9271), anti-
Akt (9272), anti-phospho-p44/p42 MAP kinase (9106), and anti-p44/42
MAP kinase (9102) (purchased from New England Biolabs, Beverly, MA);
and anti-bactin (Sigma-Aldrich).
Kit sequencing
Kit cDNAs were synthesized with SuperScript II reverse transcriptase (Gibco
BRL) and amplified by PCR with PFU DNA polymerase (Stratagene, LaJolla,
CA). The nucleotidic sequence was determined from five independent RT-
PCR amplifications. The exon 17 was amplified by PCR using PFU DNA poly-
merase, and PCR products were sequenced with the forward primer 50-CCT
TTTCTCCCCCAACATGT-30 and the reverse primer 50-TGGAGAAAGGTACT
CACATT-30.
Kit mutagenesis
The murine wild-type Kit expression vector (pEF-BOS-Kitwt) was supplied by
Dr. M. Mizuki. The KitD814Y and KitD818Ymutants into the pEF-Bos expression
vector were generated by mutagenesis of the wild-type Kit cDNA using the
QuikChange Site-Directed Mutagenesis System (Stratagene, LaJolla, CA).
Transfections
Fifty micrograms of the plasmids pEF-BOS, pEF-bos-Kitwt, pEF-BOS-
KitD814Y, pEF-BOS-KitD818Y, or LXSN-KitD814V (Casteran et al., 2003) and/or
5 mg of the selection vector pMSCV-NeoR (Clontech, Palo Alto, CA) were
transfected by electroporation (240 V, 960 mF) using a BioRad gene pulser
in 23 107 663 or 633 HS1 cells. Stable transfectants were selected in growth
medium containing 800 mg/ml G418 (Invitrogen) in the presence of Epo
(1 U/ml).
In vitro kinase assay
After incubation of Kit immunoprecipitates with protein G Sepharose beads
(Pharmacia), the beads were pelleted and washed twice with lysis buffer.
Next, beads were resuspended and washed in kinase buffer (20 mM PIPES,
10 mM MnCl2). Kinase reaction was performed for 10 min at 20ºC in 30 ml of
kinase buffer supplemented with [g-32P ATP] (10 mCi). Reactions were476terminated by the addition of an equal volume of gel loading buffer. After
SDS-PAGE, the gels were electrotransferred onto hybond nitrocellulose
membrane (Amersham Pharmacia Biotech, UK), and the kinase reaction
products were detected by autoradiography.
In vivo tumorigenicity of cells
Cells (107 cells/500 ml in aMEMmedium containing 2%FBS) were injected by
subcutaneous route into 8- to 10-week-old female nude mice. Tumor nod-
ules were taken off when the tumormass reached at least 0.5 cm in diameter.
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